|
| Press Releases |
|
 |
|
| Wednesday, April 3, 2024 |
|
|
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics |
| Eisai Co., Ltd. announced today that its French sales subsidiary Eisai S.A.S. entered into an agreement to transfer the rights in France, the French Overseas Territories and Algeria (the "Territory") for the antipsychotic, "Loxapac" (generic name: loxapine) and the Parkinson's disease treatment "Parkinane LP" (generic name: trihexyphenidyl hydrochloride) to CNX Therapeutics Limited (Headquarters: London, UK, "CNX"). more info >> |
|
| Monday, April 1, 2024 |
|
|
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA |
| Eisai Co., Ltd. and Biogen Inc. announced today that Eisai submitted to the U.S. Food andDrug Administration (FDA) a Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing. more info >> |
|
| Friday, March 29, 2024 |
|
|
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical |
| Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium disturbance treatment Merislon (generic name: betahistine mesilate) and muscle relaxant Myonal (generic name: eperisone hydrochloride) in Japan to Kaken Pharmaceutical Co., Ltd. more info >> |
|
|
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture |
| Eisai Co., Ltd. announced today that "NouKNOW", Eisai's self-check tool for brain health, was certified as a "ME-BYO BRAND" by Kanagawa prefecture. more info >> |
|
|
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024 |
| Eisai Co., Ltd. announced today that drug discovery research conducted on lemborexant (brand name: Dayvigo), the dual orexin receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2024 by the PSJ. more info >> |
|
| Thursday, March 21, 2024 |
|
|
Lifenet and Eisai Co-Develop Dementia Insurance "be" |
| LIFENET INSURANCE COMPANY and Eisai Co., Ltd. announced today that they have co-developed Dementia Insurance "be", a dementia insurance that supports early detection and treatment of dementia and mild cognitive impairment (hereafter, "MCI") as one of the initiatives under the capital and business alliance agreement concluded in August 2022 for collaboration in dementia and other areas. more info >> |
|
|
Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace |
| Eisai Co., Ltd. announced today that it has been selected for the first time by the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange (TSE) as one of the Nadeshiko Brand 2024, as a listed company excelling in the promotion of women in the workplace. more info >> |
|
| Wednesday, March 6, 2024 |
|
|
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients |
| Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has decided to invest up to 15 million USD in C2N Diagnostics LLC to support C2N's efforts to expand the availability, accessibility, affordability and utilization of blood-based tests for the diagnosis of Alzheimer's disease (AD) in the U.S. more info >> |
|
|
エーザイ、早期アルツハイマー病の診断の簡便化を支援するためC2N Diagnostics LLCに出資 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、当社米国子会社エーザイ・インクが、C2N Diagnostics LLC（本社：米国ミズーリ州セントルイス 以下 C2N）による米国におけるアルツハイマー病（AD）の血液診断の実用化ならびに、アクセス、アフォーダビリティ、および利用の拡大に向けた取り組みを支援するため、同社に最大15百万米ドルの出資を決定したことをお知らせします。 more info >> |
|
| Wednesday, July 31, 2019 |
|
|
エーザイ、E2082の臨床第I相試験（治験）における死亡例の発生について |
| 当社が日本国内で実施していた健康成人を対象とした臨床第I相試験（治験）において、2019 年6 月に、1 名の被験者様が治験薬の投与を完了後にお亡くなりになりました。被験者様のご冥福をお祈り申し上げると共に、ご遺族様には謹んでお悔やみ申し上げます。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Big CIO Show 2024 Paves the Way for Next-Gen Technological Leadership in AI
Apr 15, 2024 19:40 HKT/SGT
|
|
|
New circuit challenge for TOYOTA GAZOO Racing
Apr 15, 2024 17:21 JST
|
|
|
茶百道（2555.HK）正在招股：引领现制茶饮赛道 营收净利显著提升
Apr 15, 2024 15:02 HKT/SGT
|
|
|
茶百道（2555.HK）正在招股：引領現製茶飲賽道 營收淨利顯著提升
Apr 15, 2024 14:58 HKT/SGT
|
|
|
Montage of Singapore Season 2 Launches to Acclaim: Promoting unity across Singapore through insightful conversations
Apr 15, 2024 13:52 HKT/SGT
|
|
|
「LEXUS OVERTRAIL CAMP 2024」を開催
Apr 15, 2024 13:30: JST
|
|
|
Wider Risks of Online Piracy in Singapore Continue to be Felt as Singapore Courts Order More Sites Blocked
Apr 15, 2024 12:26 HKT/SGT
|
|
|
Seamless for Science: Revolutionizing Literature Reviews with Advanced AI and Real Database Access
Apr 15, 2024 11:00 HKT/SGT
|
|
|
Seamless For Science: 利用先進的人工智慧和真實資料庫革新文獻綜述
Apr 15, 2024 11:00 HKT/SGT
|
|
|
Seamless For Science: 利用先进的人工智能和真实数据库革新文献综述
Apr 15, 2024 11:00 HKT/SGT
|
|
|
BLUETTI Leads the Charge Towards Greener Living this Earth Day 2024
Apr 15, 2024 10:00 HKT/SGT
|
|
|
InnoEX promotes Hong Kong as international I&T hub
Apr 13, 2024 20:00: JST
|
|
|
InnoEX promotes Hong Kong as international I&T hub
Apr 13, 2024 19:00 HKT/SGT
|
|
|
Moxy.io Welcomes Former UBS CFO Thomas Gustinis to Its Executive Team and to the board of the Moxy Foundation
Apr 12, 2024 19:20 HKT/SGT
|
|
|
TOYOTA GAZOO Racing back on asphalt for Croatian challenge
Apr 12, 2024 19:36 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
